Table 2.

Association between mtDNA content and clinicopathologic variables of patients receiving either FAC/FEC or CMF first-line chemotherapy treatment for their recurrent disease (advanced cohort)

mtDNA lowmtDNA high
Characteristicn (%)n (%)P
Age (at recurrence)
 ≤4514 (23.3%)20 (32.8%)0.1
 >45–5525 (41.7%)15 (24.6%)
 >5521 (35.0%)26 (42.6%)
Menopausal status (at recurrence)
 Pre30 (50.0%)31 (50.8%)1
 Post30 (50.0%)30 (49.2%)
Tumor size
 T1 (≤2 cm)17 (28.8%)17 (28.3%)0.8
 T2 (>2–5 cm)32 (54.2%)30 (50.0%)
 T3/4 (>5 cm)10 (16.9%)13 (21.7%)
 Unknown11
Nodal status
 017 (28.3%)25 (41.0%)0.3
 1–315 (25.0%)13 (21.3%)
 >328 (46.7%)23 (37.7%)
Grade (GGI)
 18 (15.1%)5 (8.5%)0.3
 214 (26.4%)22 (37.3%)
 331 (58.5%)32 (54.2%)
 Unknown72
ER status
 Negative26 (43.3%)40 (65.6%)0.018
 Positive34 (56.7%)21 (34.4%)
PR status
 Negative38 (63.3%)41 (67.2%)0.7
 Positive22 (36.7%)20 (32.8%)
HER2 status
 Balanced38 (71.7%)46 (76.7%)0.7
 Amplified15 (28.3%)14 (23.3%)
 Unknown71
Dominant relapse site
 Soft tissue5 (8.3%)6 (9.8%)0.8
 Bone8 (13.3%)11 (18.0%)
 Visceral47 (78.3%)44 (72.1%)
Disease-free interval
 ≤1 year19 (31.7%)26 (42.6%)0.3
 >1–3 years29 (48.3%)28 (45.9%)
 >3 years12 (20.0%)7 (11.5%)
Hormonal consolidation therapy
 No44 (74.6%)47 (77.0%)0.8
 Yes15 (25.4%)14 (23.0%)
 Unknown1